These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 9081136

  • 1. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebo-controlled double-blind trial.
    Diehm C, Balzer K, Bisler H, Bulling B, Camci M, Creutzig A, Gruss JD, Horsch S, Odemar F, Piehler U, Rogatti W, Scheffler P, Spengel F, Treese N, Turowski A, Waldhausen P, Weber B, Weiss T.
    J Vasc Surg; 1997 Mar; 25(3):537-44. PubMed ID: 9081136
    [Abstract] [Full Text] [Related]

  • 2. Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication.
    Mangiafico RA, Messina R, Attinà T, Dell'Arte S, Giuliano L, Malatino LS.
    Angiology; 2000 Jun; 51(6):441-9. PubMed ID: 10870853
    [Abstract] [Full Text] [Related]

  • 3. Treatment of severe intermittent claudication with PGE1--a short-term vs a long-term infusion plan--a 20 week, European randomized trial--analysis of efficacy and costs.
    Belcaro G, Laurora G, Nicolaides AN, Agus G, Cesarone MR, DeSanctis MT, Incandela L, Ricci A, Cazaubon M, Ippolito E, Barsotti A, Vasdekis S, Ledda A, Iacobitti P, Christopoulos D, Errichi BM, Helmis H, Cornelli U, Ramaswami G, Bucci M, Ferrari PG, Corsi M, Pomante P, Mezzanotte L, Geroulakos G.
    Angiology; 1998 Nov; 49(11):885-94; discussion 895. PubMed ID: 9822044
    [Abstract] [Full Text] [Related]

  • 4. PGE(1) treatment of severe intermittent claudication (short-term versus long-term, associated with exercise)--efficacy and costs in a 20-week, randomized trial.
    Belcaro G, Nicolaides AN, Agus G, Cesarone MR, Geroulakos G, Pellegrini L, De Sanctis MT, Incandela L, Ricci A, Mondani P, De Angelis R, Ippolito E, Barsotti A, Vasdekis S, Ledda A, Christopoulos D, Errichi BM, Helmis H, Cornelli U, Ramaswami G, Dugall M, Bucci M, Martines G, Ferrari PG, Corsi M, Di Francescantonio D.
    Angiology; 2000 Aug; 51(8 Pt 2):S15-26. PubMed ID: 10959507
    [Abstract] [Full Text] [Related]

  • 5. [European trial of PGE1 alpha cyclodextrin. Short-term vs. long-term therapy in intermittent claudication].
    Laurora G, Corsi M, Bucci M, Cesarone MR, Belcaro G, Dugall M.
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):21-9. PubMed ID: 10658441
    [Abstract] [Full Text] [Related]

  • 6. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication.
    Belch JJ, Bell PR, Creissen D, Dormandy JA, Kester RC, McCollum RD, Mizushima Y, Ruckley CV, Scurr JH, Wolfe JH.
    Circulation; 1997 May 06; 95(9):2298-302. PubMed ID: 9142008
    [Abstract] [Full Text] [Related]

  • 7. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
    Böger RH, Bode-Böger SM, Thiele W, Creutzig A, Alexander K, Frölich JC.
    J Am Coll Cardiol; 1998 Nov 06; 32(5):1336-44. PubMed ID: 9809945
    [Abstract] [Full Text] [Related]

  • 8. [Treatment of severe intermittent claudication: ORACLE-PGE1 short term study. A randomised 40-week study. Evaluation of efficacy and costs].
    Cesarone MR, Belcaro G, Nicolaides AN, Griffin M, Geroulakos G, Ramaswami G, Cazaubon M, Barsotti A, Vasdekis S, Christopoulos D, Agus G, Bavera P, Mondani P, Ippolito E, Flenda F.
    Minerva Cardioangiol; 2002 Dec 06; 50(6):683-90. PubMed ID: 12473989
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Improvement of peripheral and cardiopulmonary performance after a short-term exercise program with additive prostaglandin E1.
    Cachovan M, Rogatti W.
    Angiology; 2001 Jun 06; 52(6):381-91. PubMed ID: 11437028
    [Abstract] [Full Text] [Related]

  • 16. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group.
    Abraham E, Baughman R, Fletcher E, Heard S, Lamberti J, Levy H, Nelson L, Rumbak M, Steingrub J, Taylor J, Park YC, Hynds JM, Freitag J.
    Crit Care Med; 1999 Aug 06; 27(8):1478-85. PubMed ID: 10470753
    [Abstract] [Full Text] [Related]

  • 17. [Rehabilitation program in patients with moderate-to-severe intermittent claudication: immediate results and one year follow-up].
    Rossini D, Bulckaen M, Di Marco S, Giovannetti R, Giuntoli F, Lacopetti L, Vergoni W.
    Monaldi Arch Chest Dis; 2007 Jun 06; 68(2):110-4. PubMed ID: 17886772
    [Abstract] [Full Text] [Related]

  • 18. [Severe intermittent claudication: PGE1 treatment. A 40-week registry, efficacy and costs].
    Luzzi R, Belcaro G, Ippolito E, Dugall M, Cesarone MR, Scoccianti M, Errichi BM, Pellegrini L, Ciammaichella G, Ledda A, Ricci A, Cornelli U, Feragalli B, Hosoi M, Corsi M, Simeone E, Agus GB.
    Minerva Cardioangiol; 2012 Aug 06; 60(4):405-13. PubMed ID: 22858918
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.